Renalytix (RNLX) Stock Price, News & Analysis

Company Overview

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.

Key Stats

• Today's Range: $0.19 to $0.23
• 50-Day Range: $0.18 to $0.30
• 52-Week Range: $0.18 to $2.40
• Volume: 934,496 shs
• Average Volume: 1.45 million shs
• Market Capitalization: $17.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RNLX Stock Analysis - Frequently Asked Questions

How were Renalytix's earnings last quarter?

Renalytix Plc (NASDAQ:RNLX) announced its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.11) earnings per share for the quarter, hitting the consensus estimate of ($0.11). The company had revenue of $0.46 million for the quarter, compared to analysts' expectations of $0.70 million.

When did Renalytix IPO?

Renalytix (RNLX) raised $156 million in an initial public offering (IPO) on Friday, July 17th 2020. The company issued 11,000,000 shares at a price of $14.22 per share. J.P. Morgan and Stifel served as the underwriters for the IPO.

What other stocks do shareholders of Renalytix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Renalytix investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), NVIDIA (NVDA), CrowdStrike (CRWD), Broadcom (AVGO) and Meta Platforms (META).

Company Calendar

• Last Earnings: 11/14/2023
• Today: 7/26/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Computer and Technology
• Industry: Medical laboratories
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:RNLX
• CIK: 1811115
• Web: www.renalytixai.com
• Phone: 44-20-3139-2910
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.39)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$33.46 million
• Net Margins: -1,461.60%
• Pretax Margin: -1,461.42%
• Return on Equity: N/A
• Return on Assets: -281.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.53
• Quick Ratio: 0.53

Sales & Book Value

• Annual Sales: $2.29 million
• Price / Sales: 7.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.10) per share
• Price / Book: -2.07

Miscellaneous

• Outstanding Shares: 82,960,000
• Free Float: 63,059,000
• Market Cap: $17.18 million
• Optionable: Optionable
• Beta: 2.72